ASCRS 2023: Cenegermin 0.002%: Effective for corneal nerve regeneration in neurotrophic keratitis

Article

In a presentation at the American Society for Cataract and Refractive Surgery annual meeting in San Diego, Ana Balbuena-Pareja, MSc, explained how cenegermin-bkbj ophthalmic solution 0.002% (Oxervate, Dompé) had a positive effect on corneal nerve regeneration and sensation in patients with neurotrophic keratitis.

Image Credit: © WavebreakmediaMicro - stock.adobe.come

The authors concluded that the patients with neurotrophic keratitis who were treated for at least 4 weeks with cenegermin 0.002% had an overall increase in the total, main, and branch nerve densities. These results also demonstrated a significant increase in corneal sensation after cenegermin treatment. (Adobe Stock/WavebreakmediaMicro)

Ana Balbuena-Pareja, MSc, and colleagues from Tufts Medical Center, Boston, reported that cenegermin-bkbj ophthalmic solution 0.002% (Oxervate, Dompé) had a positive effect on corneal nerve regeneration and sensation in patients with neurotrophic keratitis. The investigators reported their findings at the American Society of Cataract and Refractive Surgery (ASCRS) annual meeting in San Diego.

The authors carried out a retrospective study of patients seen at the New England Eye Center for neurotrophic keratitis from January 1, 2015, to March 31, 2022.All eligible patients completed a minimum of 4 weeks of treatment with cenegermin 0.002% and had in vivo confocal microscopy images from before and after treatment available.

For each evaluation, 3 representative in vivo confocal microscopy images were selected and graded in a masked fashion for total, main, and branch nerve density.

The group comprised of 25 patients with neurotrophic keratitis (mean age, 64.2; 28.0% male) and the control group that included 20 patients (mean age, 58.4; 40%male) were similar in age and sex.

The results showed that the median total, main, and branch nerve densities were lower in the neurotrophic keratitis group before treatment, respectively, 2,301.0, 1,653.5, and 547.9 µm/mm² compared with the respective controls values, 22,253.7, 10,130.95, and 12,080.9 (p<0.001 for all comparisons).

Following treatment with cenegermin, the densities increased to 5,306.7 for total (p=0.004), main 3,452.0 (p=0.005), and branch 1,987.9 (p=0.019) nerve densities. Corneal sensation also increased after treatment from 2.3 cm to 4.1 cm (p=0.001).

The authors concluded that the patients with neurotrophic keratitis who were treated for at least 4 weeks with cenegermin 0.002% had an overall increase in the total, main, and branch nerve densities. These results also demonstrated a significant increase in corneal sensation after cenegermin treatment.

Recent Videos
Dr. Nate Lighthizer shares key takeaways from the SECO Showcase on anterior segment technology and full laser certification course offered at SECO.
Dr. Ben Casella highlights the importance of SECO to the optometric community.
Dr. Mile Brujic discusses a case series on a novel gel for lacrimal occlusion.
Dr. Julie Rodman discusses retina, imaging, and posterior segment in SECO presentations
Shan Lin, MD, and John Berdahl, MD, share their perspectives as ophthalmologists regarding the importance of comanagement.
Dr Ben Gaddie chats about his dry eye presentation at SECO and ocular surface disease.jpg
Dr. Julie Rodman previews her SECO presentations
Three EnVision Summit faculty members weigh in on the importance of comanagement in glaucoma management, where artificial intelligence will lead eye care, and what hopes are on the horizon for corneal ectasia treatments.
Shan Lin, MD, outlines a new generation of minimally invasive glaucoma surgeries (MIGS) at Glaucoma 360.
For Ashley Wallace Tucker, OD, FAAO, FSLS, Dipl ABO, last week's conference gives a unique opportunity for optometrists and ophthalmologists to collaborate.
© 2025 MJH Life Sciences

All rights reserved.